Archie Cullen Named President of BioReliance

                 Archie Cullen Named President of BioReliance

PR Newswire

ST LOUIS, March 5, 2013

ST LOUIS, March 5, 2013 /PRNewswire/ --Sigma-Aldrich^® Corporation (NASDAQ:
SIAL) today announced that its custom manufacturing and services business
unit, SAFC^® (, has appointed Archie Cullen as the new
president of BioReliance^® ( BioReliance is the
biologics and early development services business SAFC put into place to
provide customers with a portfolio that extends from development and
commercialization through testing. Cullen replaces Charles Harwood, who is
retiring following the acquisition of BioReliance by Sigma-Aldrich in January
2012 and the subsequent integration of BioReliance into SAFC over the past


In his previous position as Vice President of SAFC, Cullen played a
significant role in the acquisition of BioReliance in 2012, which enables SAFC
to provide industry leading testing services and solutions to complement
SAFC's broad product offering and strong technology platforms.

"Being able to go to market with our product offerings complemented by an
integrated testing platform is expected to create a great opportunity for SAFC
to enable new product and service solutions to our customers," stated Archie
Cullen, President of BioReliance. "Right now, each business is benefiting from
its ability to introduce and reintroduce each other to the respective customer
bases. My role will be to support a go-to-market approach with a coordinated
offering from raw materials to testing. That's what our larger customers have
been requesting."

"As individual business units, SAFC and BioReliance have each built industry
leading offerings and positive reputations. As an integrated business unit, we
see great value in the fact that we can coordinate strengths to provide a
comprehensive solution to our customers," said Gilles Cottier, President of
SAFC. "In order to ensure we maximize this value at the customer level, we
needed to appoint someone who not only understands SAFC and BioReliance but,
more importantly, someone who is intimate with the customers and their
requirements. We are fortunate enough to have that in Archie. This is a great
opportunity to drive customer value and shareholder value with Archie as the
leader of the business."

Cullen's career includes a broad range of global experience in the biopharma
sector, including time with Life Technologies and JRH Biosciences. Following
the acquisition in 2005 by Sigma-Aldrich, Cullen became Vice President of
Commercial and Technical Operations for SAFC's biosciences business unit where
he was responsible for the organization's global sales, marketing, research
and development functions. In 2009, he was promoted to Vice President of Sales
for SAFC where he headed up strategic accounts globally. Cullen holds a
Bachelor's of Science degree from the University of Glasgow and a Master of
Business of Administration degree from Open University.

"While we are excited about the appointment of Archie, I would also like to
recognize and thank Charlie Harwood on behalf of all of us here at
Sigma-Aldrich. Under his guidance BioReliance established a clear leadership
position in providing critical services to the Biopharma industry. Over the
past year he has expertly undertaken the significant transition of the
BioReliance team into SAFC. We wish him well," concluded Cottier.

The foregoing release contains forward-looking statements that can be
identified by terminology such as "is expected" or similar expressions, or by
expressed or implied discussions regarding potential future revenues from
products derived there from. You should not place undue reliance on these
statements. There can be no guarantee that the services in SAFC's service
offering will continue to meet the demands of the marketplace. Nor can there
be any guarantee that any of these services will achieve any particular levels
of revenue in the future. Such forward-looking statements reflect the current
views of management regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. In particular, management's
expectations regarding these products could be affected by, among other
things, unexpected regulatory actions or delays or government regulation
generally; the Company's ability to obtain or maintain patent or other
proprietary intellectual property protection; competition in general;
government, industry and general public pricing pressures; the impact that the
foregoing factors could have on the values attributed to the Company's assets
and liabilities as recorded in its consolidated balance sheet, and other risks
and factors referred to in Sigma-Aldrich's current Form 10-K on file with the
US Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Sigma-Aldrich is providing the information in this press release
as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

About BioReliance by SAFC: BioReliance  was acquired by Sigma-Aldrich
Corporation, in January, 2012 to supply customers access to a powerful,
single-point provider whose products and services span the drug discovery,
development and commercialization pipeline. As part of the SAFC business unit,
BioReliance is a leading provider of cost-effective contract services,
offering more than 1,000 tests or services related to biologics safety
testing, specialized toxicology and animal health services. BioReliance has
over 700 employees and has laboratory operations in Rockville, MD and
Scotland. For more information, visit

About SAFC: SAFC, the custom manufacturing and services business unit of
Sigma-Aldrich Corporation, is recognized as a top 10 global specialty
chemicals and biologics supplier. As a trusted manufacturer for the life
science and high technology industries, SAFC works closely with customers to
resolve development challenges and accelerate the product pipeline utilizing
its global "Centers of Excellence" and dedicated manufacturing facilities. Its
rich portfolio includes high-purity inorganic materials for high technology
applications, critical raw materials and extensive biologics safety testing
services for biopharmaceutical manufacturing, and complex, high-potent APIs
and key intermediates for pharmaceutical manufacturing. For more information,

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company whose biochemical, organic chemical products, kits and
services are used in scientific research, including genomic and proteomic
research, biotechnology, pharmaceutical development, the diagnosis of disease
and as key components in pharmaceutical, diagnostics and high technology SAFC
manufacturing. Sigma-Aldrich customers include more than 1.3 million
scientists and technologists in life science companies, university and
government institutions, hospitals and industry. The Company operates in 38
countries and has nearly 9,000 employees whose objective is to provide
excellent service worldwide. Sigma-Aldrich is committed to accelerating
customer success through innovation and leadership in Life Science and High
Technology. For more information about Sigma-Aldrich, please visit its website

©2013 Sigma-Aldrich Co. LLC. All rights reserved. BioReliance and SAFC are
trademarks of Sigma-Aldrich Co. LLC or its Affiliates, registered in the US
and other countries.

SOURCE Sigma-Aldrich Corporation

Website: http://
Contact: SAFC, Kristi Fortschneider, Marketing Communications Coordinator,
+1-314-286-8331 x2407; or Media, Beth Willers, Impress Labs, +1-503-928-7828,
Press spacebar to pause and continue. Press esc to stop.